<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2008-408</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-546</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Ревматоидный артрит и гепатотропные инфекции. В чем суть проблемы?</article-title><trans-title-group xml:lang="en"><trans-title>Rheumatoid arthritis and hepatotropic infections. What is the heart of the problem?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балабанова</surname><given-names>Римма Михайловна</given-names></name><name name-style="western" xml:lang="en"><surname>Balabanova</surname><given-names>R M</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>15</day><month>10</month><year>2008</year></pub-date><volume>46</volume><issue>5</issue><issue-title>№5 (2008)</issue-title><fpage>4</fpage><lpage>9</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Балабанова Р.М., 2008</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="ru">Балабанова Р.М.</copyright-holder><copyright-holder xml:lang="en">Balabanova R.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/546">https://rsp.mediar-press.net/rsp/article/view/546</self-uri></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">&lt;div&gt;&lt;p&gt;Pontisso Р., Рооп М.С., Tioiiais P. et al. Detection of hepatitis В virus DNA in mononuclear blood cells. Br. Med. J., 1984, 288, 1563-1566&lt;/p&gt;&lt;p&gt;Romet-Lemonne J.P., El-Fassi E., Haseltine W. et al. Infection of bone marrow cells by hepatitis В virus. Lancet, 1983, 2, 732&lt;/p&gt;&lt;p&gt;GattaA., GianniniC., Lampertico P. etaL Hepatotropic viruses: new in sight in pathogenesis and treatment. Clin. Expert. Rheumat., 2008, 26, 1, S33-38&lt;/p&gt;&lt;p&gt;Московская И.А., Карпова 3.C., Наумова E.A. и др. Перинатальный гепатит В и С — проблемы диагностики, лечения, профилактики. РМЖ, 2003, 11, 16, 909-913&lt;/p&gt;&lt;p&gt;Tajiri Н., Miyoshi J., Funato Sh. et al. Prospective study of mother-to-infant transmission of hepatitis С virus. Pediatr. Infect. Dis. J., 2001, 20, 10-14&lt;/p&gt;&lt;p&gt;Toubi E., Gordon S., Kessel A. et al. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis С virus infection: association with autoimmunity. J. Autoim., 2006, 27(2), 134-139&lt;/p&gt;&lt;p&gt;Козловская Л.В., Тэгай С.В., Мсишшко Е.Ю. и др. Поражение почек, ассоциированное с вирусом гепатита В и С. Cons. Med., 2002, 4, 7, 337-341&lt;/p&gt;&lt;p&gt;Olivieri I., Palazzi C., Padula A. Hepatits С virus infection and arthritis. Rheum. Dis. Clin. North Am., 2003, 29, 111-122&lt;/p&gt;&lt;p&gt;lagnocco A., Coarig J., Mammarella A et al. Joint sonography in asymptomatic patients with HCV correlated hepatitis. Clin. Expert. Rheumat., 2004, 22, 1, 43-48&lt;/p&gt;&lt;p&gt;Балабанова P.M., Шекшина E.B., Козлов Л.В. Иммунологические нарушения у пациентов РА, ассоциированные с вирусами гепатита С и В и криоглобулинемией. Тер.архив, 2004, 76(11), 74-77&lt;/p&gt;&lt;p&gt;Игнатова Т.М. Естественное течение хронической HCV-инфекции. РЖГГИ, 2002, 2, 20-28&lt;/p&gt;&lt;p&gt;Ревматология. Национальное руководство 2008. ГЭОТАР-Москва, 290-331&lt;/p&gt;&lt;p&gt;Мок M.Y., Ng W.L., Yuen M.F. et al. Safety&amp;gt; of disease modifying anti-rheumatic agents in RA patients with virus hepatitis. Clin. Expert. Rheumat., 2000, 18, 3, 363-368&lt;/p&gt;&lt;p&gt;Балабанова P.M., Братских E.B. Эффективность комплексной терапии ревматоидного артрита с сопутствующим хроническим вирусным гепатитом С. Научно-практич. ревматол. 2003, 3, 74-77&lt;/p&gt;&lt;p&gt;Шекшина Е.В., Балабанова P.M. Инфекция и ревматоидный артрит: некоторые аспекты диагностики и лечения. Инфекц. антимикроб, тер. 2003, 5, 3, 80-84&lt;/p&gt;&lt;p&gt;Calabrese L.N., Zein N., Vassilopoulos D. Safety of anti tumor necrosis factor (anti TNF) therapy in patients with chronic viral infections: hepatitis С and B, and HIV infection. Ann. Rheum. Dis. 2004, 63 (supp. 11), ii 18-24&lt;/p&gt;&lt;p&gt;Walker U.A., Tyndall A., Daikeler T. Rheumatic conditions in human immunodeficiency virus infection. Rheumatology, 2008,1,1-8&lt;/p&gt;&lt;p&gt;Calabrese L.N., Zein N. Vassilopoulos D. Hepatits В virus (HBV) reactivation with immunosuppressive therapy in rheumatic disease: assessment and preventive strategies. Ann. Rheum. Dis., 2006, 63, 8, 983990&lt;/p&gt;&lt;p&gt;Rocatello D., Fornasieri A., Giachino O. et al. Multicenter study on HCV-related cryoglobulinemia glomerulonephritis. Am. J. Kidney Dis., 2007, 49, 69-82&lt;/p&gt;&lt;p&gt;Сейланов Л.С., Балабанова P.M., Денисов Л.Н. Сравнительная эффективность реаферона и метотрексата при ревматоидном артрите. Тер. архив, 1990, 5, 41-44&lt;/p&gt;&lt;p&gt;Балабанова P.M. Ревматоидный артрит с системными проявлениями (клиника, лечение, прогноз). Дисс. д.м.н., М., 1990, 1-238&lt;/p&gt;&lt;p&gt;Ярилина А.А., Никонова М.Ф., Литвина М.Б., Балабанова P.M. Влияние а2в интерферона in vivo и in vitro на функциональную активность Т-лимфоцитов больных ревматоидным артритом. Тер. архив, 2000, 5, 9-16&lt;/p&gt;&lt;p&gt;Calabrese L.N., Zein N. Biologic agents and liver toxicity: an added concern of therapeutic opportunity? Nature Clin. Pract. Rheum., 2007, 3, 8, 422-423&lt;/p&gt;&lt;p&gt;Vassilopoulos D., Calabrese L.N. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic disease and co-existing chronic viral infections. Curr. Opin. Rheum., 2007, 19, 619-625&lt;/p&gt;&lt;p&gt;BergL., LampaJ., RodbergS. etal. Increased peripheral T-cell reactivity to microbial antigens and collagen type II in RA after treatment with soluble TNF alpha receptors. Ann. Rheum. Dis., 2001, 60, 133-139&lt;/p&gt;&lt;p&gt;Silverman G.J. , Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-В cell therapy. Arth. Rheum., 2003, 48, 1484-1492&lt;/p&gt;&lt;p&gt;Zaja F., De Vita S., Mazzaro С. et al. Efficiacy and safety of Rituximab in type II mixed cryoglobulinemia. Blood, 2003, 101, 3827-3834&lt;/p&gt;&lt;p&gt;Cacoub P., Delluc A., Saadoun D. et al. Anti CD&lt;/p&gt;&lt;p&gt;monoclonal antibody (Rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann. Rheum. Dis., 2008, 67, 3, 283-287&lt;/p&gt;&lt;p&gt;Galeazzi М., Bellisai F., Manganelli S. et al. Cyclosporine A for the treatment of autoimmune disod- ers in HCV infected patients. Autoimmun. Rev., 2006, 5, 493-498&lt;/p&gt;&lt;p&gt;Antonelli A. Ferry C., Galeazzi M et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin. Expert. Rheumat., 2008, 26, 1, 39-47&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation><mixed-citation xml:lang="en">&lt;div&gt;&lt;p&gt;Pontisso Р., Рооп М.С., Tioiiais P. et al. Detection of hepatitis В virus DNA in mononuclear blood cells. Br. Med. J., 1984, 288, 1563-1566&lt;/p&gt;&lt;p&gt;Romet-Lemonne J.P., El-Fassi E., Haseltine W. et al. Infection of bone marrow cells by hepatitis В virus. Lancet, 1983, 2, 732&lt;/p&gt;&lt;p&gt;GattaA., GianniniC., Lampertico P. etaL Hepatotropic viruses: new in sight in pathogenesis and treatment. Clin. Expert. Rheumat., 2008, 26, 1, S33-38&lt;/p&gt;&lt;p&gt;Московская И.А., Карпова 3.C., Наумова E.A. и др. Перинатальный гепатит В и С — проблемы диагностики, лечения, профилактики. РМЖ, 2003, 11, 16, 909-913&lt;/p&gt;&lt;p&gt;Tajiri Н., Miyoshi J., Funato Sh. et al. Prospective study of mother-to-infant transmission of hepatitis С virus. Pediatr. Infect. Dis. J., 2001, 20, 10-14&lt;/p&gt;&lt;p&gt;Toubi E., Gordon S., Kessel A. et al. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis С virus infection: association with autoimmunity. J. Autoim., 2006, 27(2), 134-139&lt;/p&gt;&lt;p&gt;Козловская Л.В., Тэгай С.В., Мсишшко Е.Ю. и др. Поражение почек, ассоциированное с вирусом гепатита В и С. Cons. Med., 2002, 4, 7, 337-341&lt;/p&gt;&lt;p&gt;Olivieri I., Palazzi C., Padula A. Hepatits С virus infection and arthritis. Rheum. Dis. Clin. North Am., 2003, 29, 111-122&lt;/p&gt;&lt;p&gt;lagnocco A., Coarig J., Mammarella A et al. Joint sonography in asymptomatic patients with HCV correlated hepatitis. Clin. Expert. Rheumat., 2004, 22, 1, 43-48&lt;/p&gt;&lt;p&gt;Балабанова P.M., Шекшина E.B., Козлов Л.В. Иммунологические нарушения у пациентов РА, ассоциированные с вирусами гепатита С и В и криоглобулинемией. Тер.архив, 2004, 76(11), 74-77&lt;/p&gt;&lt;p&gt;Игнатова Т.М. Естественное течение хронической HCV-инфекции. РЖГГИ, 2002, 2, 20-28&lt;/p&gt;&lt;p&gt;Ревматология. Национальное руководство 2008. ГЭОТАР-Москва, 290-331&lt;/p&gt;&lt;p&gt;Мок M.Y., Ng W.L., Yuen M.F. et al. Safety&amp;gt; of disease modifying anti-rheumatic agents in RA patients with virus hepatitis. Clin. Expert. Rheumat., 2000, 18, 3, 363-368&lt;/p&gt;&lt;p&gt;Балабанова P.M., Братских E.B. Эффективность комплексной терапии ревматоидного артрита с сопутствующим хроническим вирусным гепатитом С. Научно-практич. ревматол. 2003, 3, 74-77&lt;/p&gt;&lt;p&gt;Шекшина Е.В., Балабанова P.M. Инфекция и ревматоидный артрит: некоторые аспекты диагностики и лечения. Инфекц. антимикроб, тер. 2003, 5, 3, 80-84&lt;/p&gt;&lt;p&gt;Calabrese L.N., Zein N., Vassilopoulos D. Safety of anti tumor necrosis factor (anti TNF) therapy in patients with chronic viral infections: hepatitis С and B, and HIV infection. Ann. Rheum. Dis. 2004, 63 (supp. 11), ii 18-24&lt;/p&gt;&lt;p&gt;Walker U.A., Tyndall A., Daikeler T. Rheumatic conditions in human immunodeficiency virus infection. Rheumatology, 2008,1,1-8&lt;/p&gt;&lt;p&gt;Calabrese L.N., Zein N. Vassilopoulos D. Hepatits В virus (HBV) reactivation with immunosuppressive therapy in rheumatic disease: assessment and preventive strategies. Ann. Rheum. Dis., 2006, 63, 8, 983990&lt;/p&gt;&lt;p&gt;Rocatello D., Fornasieri A., Giachino O. et al. Multicenter study on HCV-related cryoglobulinemia glomerulonephritis. Am. J. Kidney Dis., 2007, 49, 69-82&lt;/p&gt;&lt;p&gt;Сейланов Л.С., Балабанова P.M., Денисов Л.Н. Сравнительная эффективность реаферона и метотрексата при ревматоидном артрите. Тер. архив, 1990, 5, 41-44&lt;/p&gt;&lt;p&gt;Балабанова P.M. Ревматоидный артрит с системными проявлениями (клиника, лечение, прогноз). Дисс. д.м.н., М., 1990, 1-238&lt;/p&gt;&lt;p&gt;Ярилина А.А., Никонова М.Ф., Литвина М.Б., Балабанова P.M. Влияние а2в интерферона in vivo и in vitro на функциональную активность Т-лимфоцитов больных ревматоидным артритом. Тер. архив, 2000, 5, 9-16&lt;/p&gt;&lt;p&gt;Calabrese L.N., Zein N. Biologic agents and liver toxicity: an added concern of therapeutic opportunity? Nature Clin. Pract. Rheum., 2007, 3, 8, 422-423&lt;/p&gt;&lt;p&gt;Vassilopoulos D., Calabrese L.N. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic disease and co-existing chronic viral infections. Curr. Opin. Rheum., 2007, 19, 619-625&lt;/p&gt;&lt;p&gt;BergL., LampaJ., RodbergS. etal. Increased peripheral T-cell reactivity to microbial antigens and collagen type II in RA after treatment with soluble TNF alpha receptors. Ann. Rheum. Dis., 2001, 60, 133-139&lt;/p&gt;&lt;p&gt;Silverman G.J. , Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-В cell therapy. Arth. Rheum., 2003, 48, 1484-1492&lt;/p&gt;&lt;p&gt;Zaja F., De Vita S., Mazzaro С. et al. Efficiacy and safety of Rituximab in type II mixed cryoglobulinemia. Blood, 2003, 101, 3827-3834&lt;/p&gt;&lt;p&gt;Cacoub P., Delluc A., Saadoun D. et al. Anti CD&lt;/p&gt;&lt;p&gt;monoclonal antibody (Rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann. Rheum. Dis., 2008, 67, 3, 283-287&lt;/p&gt;&lt;p&gt;Galeazzi М., Bellisai F., Manganelli S. et al. Cyclosporine A for the treatment of autoimmune disod- ers in HCV infected patients. Autoimmun. Rev., 2006, 5, 493-498&lt;/p&gt;&lt;p&gt;Antonelli A. Ferry C., Galeazzi M et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin. Expert. Rheumat., 2008, 26, 1, 39-47&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
